{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:55:57Z","timestamp":1781045757072,"version":"3.54.1"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2022-0108_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The four-tiered peritoneal regression grading score (PRGS) is used for histological response evaluation in patients with peritoneal metastasis (PM) treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Four quadrant biopsies (QBs) from the parietal peritoneum should be assessed by PRGS, but consensus on biopsy site strategy for follow-up biopsies during repeated PIPACs is lacking. We aimed to evaluate whether there is a difference between PRGS in QBs from clips marked PM (QB-CM) compared to biopsies from PM with the visually most malignant features (worst biopsy, WB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2022-0108_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, descriptive study. During the first PIPAC, index QBs sites were marked with metal clips. During the second PIPAC, an independent surgical oncologist selected biopsy site for WB and biopsies were taken from QB-CM and WB. One blinded pathologist evaluated all biopsies according to PRGS. From each biopsy, three step sections were stained H&amp;E, followed by an immunostained section, and another three step sections stained H&amp;E.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2022-0108_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-four patients were included from March 2020 to May 2021. Median age 64 years. Maximum mean PRGS in QB-CM at PIPAC 1 was 3.3 (SD 1.2). Maximum mean\u00a0PRGS in QB-CM at PIPAC 2 was 2.6 (SD 1.2), whereas mean PRGS in WB at PIPAC 2 was 2.4 (SD 1.3). At PIPAC 2, there was agreement between maximum PRGS from QB-CM and PRGS from WB in 21 patients. Maximum PRGS from QB-CM was higher in nine and lower in four patients, compared to PRGS from WB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2022-0108_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biopsies from QB-CM did not overestimate treatment response compared to biopsies from WB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2022-0108","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T13:13:40Z","timestamp":1653916420000},"page":"143-148","source":"Crossref","is-referenced-by-count":12,"title":["Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC)"],"prefix":"10.1515","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0705-9465","authenticated-orcid":false,"given":"Mojib","family":"Fallah","sequence":"first","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Upper GI and HPB Section, Department of Surgery , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Department of Pathology , Odense University Hospital , Odense , Denmark"},{"name":"Department of Clinical Research , Faculty of Health Sciences, University of Southern Denmark , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Ainsworth","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Upper GI and HPB Section, Department of Surgery , Odense University Hospital , Odense , Denmark"},{"name":"Department of Clinical Research , Faculty of Health Sciences, University of Southern Denmark , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus W.","family":"Fristrup","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Upper GI and HPB Section, Department of Surgery , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7270-5005","authenticated-orcid":false,"given":"Michael B.","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Upper GI and HPB Section, Department of Surgery , Odense University Hospital , Odense , Denmark"},{"name":"Department of Clinical Research , Faculty of Health Sciences, University of Southern Denmark , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Department of Clinical Research , Faculty of Health Sciences, University of Southern Denmark , Odense , Denmark"},{"name":"Department of Oncology , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line S.","family":"Tarpgaard","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Department of Oncology , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Graversen","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center , Odense University Hospital , Odense , Denmark"},{"name":"Upper GI and HPB Section, Department of Surgery , Odense University Hospital , Odense , Denmark"},{"name":"Department of Clinical Research , Faculty of Health Sciences, University of Southern Denmark , Odense , Denmark"},{"name":"Open Patient data Explorative Network (OPEN) , Odense University Hospital, Region of Southern Denmark , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"2025120909233464123_j_pp-2022-0108_ref_001","doi-asserted-by":"crossref","unstructured":"Solass, W, Hetzel, A, Nadiradze, G, Sagynaliev, E, Reymond, MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012;26:1849\u201355. https:\/\/doi.org\/10.1007\/s00464-012-2148-0.","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909233464123_j_pp-2022-0108_ref_002","doi-asserted-by":"crossref","unstructured":"Graversen, M, Pedersen, PB, Mortensen, MB. Environmental safety during the administration of pressurized IntraPeritoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum 2016;1:203\u20138. https:\/\/doi.org\/10.1515\/pp-2016-0019.","DOI":"10.1515\/pp-2016-0019"},{"key":"2025120909233464123_j_pp-2022-0108_ref_003","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Bjerregaard, JK, Fristrup, CW, Pfeiffer, P, Mortensen, MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 2018;10:1758835918777036. https:\/\/doi.org\/10.1177\/1758835918777036.","DOI":"10.1177\/1758835918777036"},{"key":"2025120909233464123_j_pp-2022-0108_ref_004","doi-asserted-by":"crossref","unstructured":"Alyami, M, Hubner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al.. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(19)30318-3.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2025120909233464123_j_pp-2022-0108_ref_005","unstructured":"Graversen, M, Detlefsen, S, Knudsen, AO, Pfeiffer, P, Mortensen, MB. [Pressurised intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of peritoneal metastases]. Ugeskr Laeger 2019:181."},{"key":"2025120909233464123_j_pp-2022-0108_ref_006","doi-asserted-by":"crossref","unstructured":"Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025120909233464123_j_pp-2022-0108_ref_007","doi-asserted-by":"crossref","unstructured":"Hynninen, J, Lavonius, M, Oksa, S, Grenman, S, Carpen, O, Auranen, A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol 2013;128:229\u201332. https:\/\/doi.org\/10.1016\/j.ygyno.2012.11.007.","DOI":"10.1016\/j.ygyno.2012.11.007"},{"key":"2025120909233464123_j_pp-2022-0108_ref_008","doi-asserted-by":"crossref","unstructured":"Koh, JL, Yan, TD, Glenn, D, Morris, DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 2009;16:327\u201333. https:\/\/doi.org\/10.1245\/s10434-008-0234-2.","DOI":"10.1245\/s10434-008-0234-2"},{"key":"2025120909233464123_j_pp-2022-0108_ref_009","doi-asserted-by":"crossref","unstructured":"Low, RN, Barone, RM, Rousset, P. Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation. Eur J Surg Oncol 2021;47:65\u201374. https:\/\/doi.org\/10.1016\/j.ejso.2019.02.030.","DOI":"10.1016\/j.ejso.2019.02.030"},{"key":"2025120909233464123_j_pp-2022-0108_ref_010","doi-asserted-by":"crossref","unstructured":"Rubbia-Brandt, L, Giostra, E, Brezault, C, Roth, AD, Andres, A, Audard, V, et al.. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299\u2013304. https:\/\/doi.org\/10.1093\/annonc\/mdl386.","DOI":"10.1093\/annonc\/mdl386"},{"key":"2025120909233464123_j_pp-2022-0108_ref_011","doi-asserted-by":"crossref","unstructured":"Rodel, C, Martus, P, Papadoupolos, T, Fuzesi, L, Klimpfinger, M, Fietkau, R, et al.. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688\u201396. https:\/\/doi.org\/10.1200\/jco.2005.02.1329.","DOI":"10.1200\/JCO.2005.02.1329"},{"key":"2025120909233464123_j_pp-2022-0108_ref_012","doi-asserted-by":"crossref","unstructured":"Mandard, AM, Dalibard, F, Mandard, JC, Marnay, J, Henry-Amar, M, Petiot, JF, et al.. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c.","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"key":"2025120909233464123_j_pp-2022-0108_ref_013","doi-asserted-by":"crossref","unstructured":"Chun, YS, Cooper, HS, Cohen, SJ, Konski, A, Burtness, B, Denlinger, CS, et al.. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011;18:3601\u20137. https:\/\/doi.org\/10.1245\/s10434-011-2086-4.","DOI":"10.1245\/s10434-011-2086-4"},{"key":"2025120909233464123_j_pp-2022-0108_ref_014","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Detlefsen, S, Carr, NJ, Bibeau, F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum 2016;1:99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909233464123_j_pp-2022-0108_ref_015","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Carr, NJ, Bibeau, F, Neureiter, D, Jager, T, et al.. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology 2019;74:1014\u201324. https:\/\/doi.org\/10.1111\/his.13829.","DOI":"10.1111\/his.13829"},{"key":"2025120909233464123_j_pp-2022-0108_ref_016","doi-asserted-by":"crossref","unstructured":"Detlefsen, S, Windedal, T, Bibeau, F, Bruhn, LV, Carr, N, Graversen, M, et al.. Role of immunohistochemistry for interobserver agreement of Peritoneal Regression Grading Score (PRGS) in peritoneal metastasis. Hum Pathol 2022;120:77\u201387. https:\/\/doi.org\/10.1016\/j.humpath.2021.12.005.","DOI":"10.1016\/j.humpath.2021.12.005"},{"key":"2025120909233464123_j_pp-2022-0108_ref_017","doi-asserted-by":"crossref","unstructured":"Benzerdjeb, N, Durieux, E, Tantot, J, Isaac, S, Fontaine, J, Harou, O, et al.. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology 2020;77:548\u201359. https:\/\/doi.org\/10.1111\/his.14092.","DOI":"10.1111\/his.14092"},{"key":"2025120909233464123_j_pp-2022-0108_ref_018","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Asmussen, J, Mahdi, B, Fristrup, C, Pfeiffer, P, et al.. Treatment of peritoneal carcinomatosis with pressurized IntraPeritoneal aerosol chemotherapy\u00a0\u2013 PIPAC-OPC2. Pleura Peritoneum 2018;3:20180108. https:\/\/doi.org\/10.1515\/pp-2018-0108.","DOI":"10.1515\/pp-2018-0108"},{"key":"2025120909233464123_j_pp-2022-0108_ref_019","doi-asserted-by":"crossref","unstructured":"Rovers, KP, Wassenaar, ECE, Lurvink, RJ, Creemers, GM, Burger, JWA, Los, M, et al.. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol 2021;28:5311\u201326. https:\/\/doi.org\/10.1245\/s10434-020-09558-4.","DOI":"10.1245\/s10434-020-09558-4"},{"key":"2025120909233464123_j_pp-2022-0108_ref_020","doi-asserted-by":"crossref","unstructured":"Dumont, F, Senellart, H, Pein, F, Campion, L, Glehen, O, Goere, D, et al.. Phase I\/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design. Pleura Peritoneum 2018;3: 20180120. https:\/\/doi.org\/10.1515\/pp-2018-0120.","DOI":"10.1515\/pp-2018-0120"},{"key":"2025120909233464123_j_pp-2022-0108_ref_021","doi-asserted-by":"crossref","unstructured":"Eveno, C, Jouvin, I, Pocard, M. PIPAC EstoK 01: pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum 2018;3:20180116. https:\/\/doi.org\/10.1515\/pp-2018-0116.","DOI":"10.1515\/pp-2018-0116"},{"key":"2025120909233464123_j_pp-2022-0108_ref_022","doi-asserted-by":"crossref","unstructured":"Sgarbura, O, Villeneuve, L, Alyami, M, Bakrin, N, Torrent, JJ, Eveno, C, et al.. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): still standardized or on the verge of diversification? Eur J Surg Oncol 2021;47:149\u201356. https:\/\/doi.org\/10.1016\/j.ejso.2020.08.020.","DOI":"10.1016\/j.ejso.2020.08.020"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2022-0108\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2022-0108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:01:27Z","timestamp":1765278087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2022-0108\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,6]]},"published-print":{"date-parts":[[2022,9,13]]}},"alternative-id":["10.1515\/pp-2022-0108"],"URL":"https:\/\/doi.org\/10.1515\/pp-2022-0108","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]}}}